Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 8/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2078658 | 1.00 | ATM (0.34) | ATMMEN1KMT2ASRCALDH1A1 | |
| SCHEMBL2078653 | 1.00 | ATM (0.34) | ATMMEN1KMT2ASRCALDH1A1 | |
| SCHEMBL2079078 | 0.91 | SRC (0.34) | MEN1KMT2ASRCALDH1A1KDM4E | |
| SCHEMBL2080384 | 0.85 | ALDH1A1 (0.34) | MEN1KMT2AALDH1A1HSD17B10USP2 | |
| SCHEMBL2080381 | 0.85 | ALDH1A1 (0.34) | MEN1KMT2AALDH1A1HSD17B10USP2 | |
| SCHEMBL2080379 | 0.85 | ALDH1A1 (0.34) | MEN1KMT2AALDH1A1HSD17B10USP2 | |
| SCHEMBL2079462 | 0.85 | CHRM2 (0.37) | ATMMEN1KMT2ASRCALDH1A1 | |
| SCHEMBL2079458 | 0.85 | CHRM2 (0.37) | ATMMEN1KMT2ASRCALDH1A1 | |
| SCHEMBL2079460 | 0.85 | CHRM2 (0.37) | ATMMEN1KMT2ASRCALDH1A1 | |
| SCHEMBL2077729 | 0.81 | SMYD3 (0.39) | ATMMEN1KMT2ASRCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906532-B2 | Antiserotonine agents; gastrointestinal disorders; irritable bowel syndrome; central nervous system disorders; Alzheimer's disease; cognition activators; analgesics; cardiovascular disorders; antidiabetic agents; sleep disorders | PFIZER INC. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-1910340-B1 | INDAZOLECARBOXAMIDE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080269211-A1 | Indazole Derivatives | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269211-A1 | Indazole Derivatives | GPR119, HRH4, HTR4 | ATM 1580/4885MEN1 851/4885KMT2A 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.